Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Reina, Kaneko"'
Autor:
Yoshihito Sakai MD, PhD, Tsuyoshi Watanabe MD, PhD, Norimitsu Wakao MD, PhD, Hiroki Matsui MD, PhD, Naoaki Osada MD, Reina Kaneko MD, Ken Watanabe PhD
Publikováno v:
Gerontology and Geriatric Medicine, Vol 9 (2023)
Objectives: The prevalence of chronic pain increases with age. It has been reported that chronic pain is associated with sarcopenia and obesity. Age-related skeletal muscle loss and fat gain are known to occur due to chronic inflammation. The aim of
Externí odkaz:
https://doaj.org/article/4bdafdde9c774ac996561394d837aefd
Autor:
Reina Kaneko, Shunsuke Ono
Publikováno v:
SAGE Open Medicine, Vol 7 (2019)
Background/objectives: The results of phase 2 and 3 clinical trials, which justify decisions regarding marketing approval for new drugs, are used for comparison of drugs in the post-marketing phase. A number of meta-analyses of approved antidiabetics
Externí odkaz:
https://doaj.org/article/1c01b509737d4972bcbb3f61671fe145
Publikováno v:
Folia Pharmacologica Japonica. 156:47-51
Antibody-drug conjugates (ADCs) combine the specific antibody and cytotoxic agent by a linker and represent a promising drug class with a wider therapeutic window than conventional chemotherapeutic agents by substantiating efficient and specific drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb8a7438450ede43673503e32fe4bad6
https://doi.org/10.1254/fpj.20076
https://doi.org/10.1254/fpj.20076
Publikováno v:
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 156(1)
Antibody-drug conjugates (ADCs) combine the specific antibody and cytotoxic agent by a linker and represent a promising drug class with a wider therapeutic window than conventional chemotherapeutic agents by substantiating efficient and specific drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b704450798c26a76f6df12b41e5c922a
https://pubmed.ncbi.nlm.nih.gov/33390481
https://pubmed.ncbi.nlm.nih.gov/33390481
Autor:
Shunsuke Ono, Reina Kaneko
Publikováno v:
SAGE Open Medicine, Vol 7 (2019)
SAGE Open Medicine
SAGE Open Medicine
Background/objectives: The results of phase 2 and 3 clinical trials, which justify decisions regarding marketing approval for new drugs, are used for comparison of drugs in the post-marketing phase. A number of meta-analyses of approved antidiabetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8149b4a958cb3f3a5251adb84edd14a2
https://doaj.org/article/1c01b509737d4972bcbb3f61671fe145
https://doaj.org/article/1c01b509737d4972bcbb3f61671fe145
Publikováno v:
Clinical pharmacology and therapeutics. 104(1)
The results of pivotal trials, which provide a rationale for marketing approval decisions for new drugs, are considered for various comparative purposes in postmarketing analyses. Using meta-regression analysis of 91 randomized controlled trials of 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf7038ad4619279ebfd5a34571282a0f
https://pubmed.ncbi.nlm.nih.gov/29071718
https://pubmed.ncbi.nlm.nih.gov/29071718
Autor:
Ryotaku Inoue, Reina Kaneko, Tsuyoshi Nakamura, Hiroshi Yuita, Tetsufumi Koga, Eiko Namba, Hatsumi Nasu, Takahide Nishi, Takashi Kagari, Yukiko Sekiguchi, Yumi Kawase, Kazuhiko Tamaki, Shintaro Nakayama, Keiko Oguchi-Oshima, Takaichi Shimozato, Noriko Masubuchi, Yumiko Mizuno, Masayoshi Asano, Takahiro Yamaguchi, Wataru Tomisato, Futoshi Nara, Hiromi Doi-Komuro
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:3083-3088
We have previously disclosed 1,2,4-oxadiazole derivative 3 as a potent S1P3-sparing S1P1 agonist. Although compound 3 exhibits potent and manageable immunosuppressive efficacy in various in vivo models, recent studies have revealed that its 1,2,4-oxa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dee7d6079550f2c98197e1e96700deda
https://doi.org/10.1016/j.bmcl.2012.03.067
https://doi.org/10.1016/j.bmcl.2012.03.067
Autor:
Hiroshi Yuita, Reina Kaneko, Masayoshi Asano, Takashi Kagari, Takaichi Shimozato, Nobuaki Watanabe, Takahide Nishi, Hiromi Doi, Wataru Tomisato, Takako Kimura, Yumiko Mizuno, Yumi Kawase, Yasuyuki Abe, Miyuki Nagasaki, Yukiko Sekiguchi, Futoshi Nara, Keiko Oguchi-Oshima, Ryotaku Inoue, Tsuyoshi Nakamura, Kazuhiko Tamaki
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:1788-1792
S1P(3)-sparing S1P(1) agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC(50) value of 4.0 nM for human S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc5d0df16308dff29d13f28a42fb0bce
https://doi.org/10.1016/j.bmcl.2011.12.019
https://doi.org/10.1016/j.bmcl.2011.12.019
Autor:
Takemichi Nakamura, Koji Matsuoka, Daiyo Terunuma, XiaoTao Ma, Reina Kaneko, Yasuaki Esumi, Tetsuo Koyama, Ken Hatano
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:4906-4910
An efficient synthesis of sialyllactosamine (SiaLacNAc) clusters using carbosilanes as core scaffolds has been accomplished by means of chemical and enzymatic approaches. N -Acetyl- d -glucosamine (GlcNAc) clusters having O -glycosidic linkage or S -
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50e102cc90adef820dadbcd83819567
https://doi.org/10.1016/j.bmcl.2010.06.066
https://doi.org/10.1016/j.bmcl.2010.06.066
Autor:
Masayoshi, Asano, Tsuyoshi, Nakamura, Yukiko, Sekiguchi, Yumiko, Mizuno, Takahiro, Yamaguchi, Kazuhiko, Tamaki, Takaichi, Shimozato, Hiromi, Doi-Komuro, Takashi, Kagari, Wataru, Tomisato, Ryotaku, Inoue, Hiroshi, Yuita, Keiko, Oguchi-Oshima, Reina, Kaneko, Futoshi, Nara, Yumi, Kawase, Noriko, Masubuchi, Shintaro, Nakayama, Tetsufumi, Koga, Eiko, Namba, Hatsumi, Nasu, Takahide, Nishi
Publikováno v:
Bioorganicmedicinal chemistry letters. 22(9)
We have previously disclosed 1,2,4-oxadiazole derivative 3 as a potent S1P(3)-sparing S1P(1) agonist. Although compound 3 exhibits potent and manageable immunosuppressive efficacy in various in vivo models, recent studies have revealed that its 1,2,4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a56291337d579236e37838536ce301d7
https://pubmed.ncbi.nlm.nih.gov/22487179
https://pubmed.ncbi.nlm.nih.gov/22487179